ClinicalTrials.gg
Active, not recruitingNCT07172698Updated Aug 31, 2026

Effects of a Multicomponent Protocol With Emphasis on Muscle Power Training on Bradykinesia in Individuals With Parkinson's Disease

An interventional study of multicomponent training with an emphasis on muscle power and traditional multicomponent training in Parkinson Disease (PD), sponsored by Federal University of Health Science of Porto Alegre. Active, not recruiting at 1 site in Brazil. Open to participants aged 50 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-08-31.

Sponsored by Federal University of Health Science of Porto Alegre · Not applicable, Interventional, and Supportive care

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
22
Allocation
Randomized
Ages
50 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 103 studies in Parkinson Disease with a site in Brazil — 19 open to participants now, 22 under way, 1 of them phase 3. Parkinson Disease · Brazil.

Enrollment
71st of 95
22 · median 34
Started
2025
with 9 others
No phase
81 of 103
15 open now
Primary completion
2026-12
later than 12 of 21 live
Registered
92nd of 103
by date
Lead sponsor
9 of 103
Federal University of Health Science of Porto Alegre

Among the 103 studies in Parkinson Disease with a site in Brazil, this one is the 71st largest by enrollment of the 95 interventional ones that give a count, is one of 10 that started in 2025, is one of 81 with no phase, reaches primary completion later than 12 of the 21 other live ones, and was the 92nd registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

19 of the 103 studies in Parkinson Disease with a site in Brazil are open now. Recruiting first, the newest first:

14 more — sign in →

All 19 open studies →

A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 50 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 103 studies in Parkinson Disease with a site in Brazil, or all of them as a file.
02

Study summary

Parkinson's disease (PD) is a chronic progressive neurological disorder that involves both motor and non-motor symptoms, culminating in functional decline and disability. One of the main symptoms of PD is bradykinesia and its deleterious effect on functionality. Muscle weakness has also been reported as an important symptom of PD, and muscle power may be even more affected and related to these symptoms. Typical conventional physical therapy treatment includes mobility exercises, strength training, gait training, and balance training, and it presents numerous benefits associated with the reduction of motor symptoms of PD. Physical therapy with power training has also been studied as an alternative to improve the ability to perform activities of daily living in other populations. However, the literature that includes power training in physiotherapeutic approaches for people with PD is scarce. Power training may minimize the problems arising from changes in motor function in older adults with PD; however, there is still a lack of evidence using this modality in the different subtypes of the disease. Knowing that motor function is associated with functional capacity and disease severity, physical therapy becomes an important treatment resource with exercises to improve muscle power. Therefore, the objective of this study is to investigate the effect of a multicomponent protocol with an emphasis on muscle power training concerning bradykinesia in individuals with rigid-akinetic type PD. A Randomized Clinical Trial will be conducted, in which individuals diagnosed with Parkinson's disease, rigid-akinetic type, classified from 1 to 3 on the Hoehn and Yahr Scale, aged between 50 and 85 years, and who sign the Informed Consent Form will participate. The individuals will be randomized into two treatment groups: G1 - traditional multicomponent training, G2 - multicomponent training with an emphasis on muscle power and G3 - control group. Assessments will be conducted at four time points for all participants: before (T0), during (T1 - 6 weeks), immediately after intervention (T3 - 12 weeks), and follow-up (T4 - 16 weeks). The assessments will consist of the analysis of: 1) motor function through the adapted Unified Parkinson's Disease Rating Scale (UPDRS III) (bradykinesia as the primary outcome); 2) mobility of the posterior chain of the trunk and lower limbs using the Wells Bench; 3) body composition by Dual-Energy X-ray Absorptiometry (DXA); 4) rigidity of the leg extensor muscles assessed by ultrasound elastography; 5) muscle power of knee extensors using a linear potentiometer (Peak Power, CEFISE); 6) functional capacity through the CounterMovement Jump - CMJ and the Sit-to-Stand Five Times Test (TSLCV); and 7) postural assessment using the NeuroPostureApp. Treatment sessions will occur twice a week for 12 weeks, lasting 60 minutes each, totaling 24 sessions for each intervention. Group 1 will perform an exercise protocol that includes warm-up, mobility, muscle strength, and flexibility. Group 2 will perform the same exercise protocol, with the caveat that, whenever feasible, exercises will be executed in the muscle power modality (at the highest possible speed). This latter training is characterized by a lower number of repetitions and a higher movement speed, guided by the therapists assisting. The progression of muscle power exercises will occur at 35%, 40%, 45%, 50%, 55%, and 60% of 1RM over the 12 weeks, distributed in 2 sets of 6 to 8 repetitions, with rest times of 60 to 120 seconds. Group 3 will undergo a protocol similar to traditional physiotherapy, without 1RM-based intensity control, periodization, or systematic load progression as applied in the other groups. Load and exercise progression will be adjusted subjectively based on the physiotherapist's clinical judgment and the participant's perceived exertion. Assessments will occur at the same time points (T0, T1, T2, and T3), and the same exercises will be performed, but intensity and exercise difficulty progression will be controlled subjectively.

03

Conditions studied

  • Parkinson Disease (PD)

Browse trials for

04

Who can participate

Ages eligible
50 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

To be included in the research, individuals must:

  • be Diagnosed with Parkinson's disease and classified as 1 to 3 on the Hoehn and Yahr Scale;
  • Present rigid akinetic PD;
  • Be Aged between 50 and 85 years;
  • Achieve a minimum score of 21 points on the (MoCa);
  • Sign the Form (ICF)

Exclusion criteria

Exclusion Criteria:

Individuals will be excluded from this study if they present:

  • Previous associated neurological diseases;
  • Vestibular system disorders;
  • Change in the pattern of levodopa use during the study;
  • Severe heart disease;
  • Uncontrolled arterial hypertension;
  • Previous spinal surgeries;
  • Tumors or infection of the spinal column;
  • Inflammatory diseases of the spinal column;
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
22 participants (actual)

Study arms

  • Experimental
    G1 - traditional multicomponent training

    Group 1 will perform an exercise protocol that includes warm-up, mobility, muscle strength, and flexibility

    Other: traditional multicomponent training

  • Experimental
    G2 - multicomponent training with an emphasis on muscle power

    Group 2 will perform the same exercise protocol, with the caveat that, whenever feasible, exercises will be executed in the muscle power modality (at the highest possible speed). This latter training is characterized by a lower number of repetitions and a higher movement speed, guided by the therapists assisting. The progression of muscle power exercises will occur at 35%, 40%, 45%, 50%, 55%, and 60% of 1RM over the 12 weeks, distributed in 2 sets of 6 to 8 repetitions, with rest times of 60 to 120 seconds.

    Other: multicomponent training with an emphasis on muscle power

  • Active comparator
    G3 - control group

    Group 3 will undergo a protocol similar to traditional physiotherapy. In this group, training intensity will not be controlled based on the one-repetition maximum (1RM) test, nor will periodization strategies or systematic load progression be applied, as performed in the other intervention groups. Load adjustments and exercise progression will be conducted subjectively, considering both the clinical judgment of the physiotherapist and the participant's perceived exertion. The exercises performed will be the same as those used in the other groups; however, exercise intensity control and progression of exercise difficulty will be implemented subjectively.

    Other: control group

Interventions

  • Othermulticomponent training with an emphasis on muscle power

    Group 2 will perform the same exercise protocol, with the caveat that, whenever feasible, exercises will be executed in the muscle power modality (at the highest possible speed). This latter training is characterized by a lower number of repetitions and a higher movement speed, guided by the therapists assisting. The progression of muscle power exercises will occur at 35%, 40%, 45%, 50%, 55%, and 60% of 1RM over the 12 weeks, distributed in 2 sets of 6 to 8 repetitions, with rest times of 60 to 120 seconds.

  • Othertraditional multicomponent training

    Group 1 will perform an exercise protocol that includes warm-up, mobility, muscle strength, and flexibility

  • Othercontrol group

    Group 3 will undergo a protocol similar to traditional physiotherapy. In this group, training intensity will not be controlled based on the one-repetition maximum (1RM) test, nor will periodization strategies or systematic load progression be applied, as performed in the other intervention groups. Load adjustments and exercise progression will be conducted subjectively, considering both the clinical judgment of the physiotherapist and the participant's perceived exertion. Assessment time points will be identical to those adopted in the other groups and will be conducted at T0, T1, T2, and T3. The exercises performed will be the same as those used in the other groups; however, exercise intensity control and progression of exercise difficulty will be implemented subjectively.

06

What researchers measure

Primary outcomes

  1. Bradykinesia

    The objective of this study is to investigate the effect of a multicomponent protocol with an emphasis on muscle power training concerning bradykinesia in individuals with rigid-akinetic type PD. This outcome will be measured using the UPDRS (Unified Parkinson's Disease Rating Scale) Part III.

    Time frame: Baseline, 6 weeks, end of intervention (12 weeks) and follow-up (16weeks)

Secondary outcomes

  1. Mobility of the posterior chain of the trunk and lower limbs

    Sit and Reach (SA) Test on the Wells Bench This tool allows the assessment of the amplitude and flexibility of the back of the trunk and lower limbs. To perform the test, the Wells bench is used, where individuals are instructed to sit with their feet in full contact with the front of the bench and their lower limbs with their hips flexed and their knees extended. The subjects are instructed to perform a trunk flexion together with a forced exhalation and to move the bench scale as far as they can. This procedure is performed three times and immediately noted by the evaluator; the value obtained in each attempt is expressed in centimeters, and the best one is selected.

    Time frame: Baseline, 6 weeks, end of intervention (12 weeks) and follow-up (16weeks)

  2. Body composition by Dual-Energy X-ray Absorptiometry (DXA)

    Dual-energy X-ray absorptiometry (DXA) is a method used to assess body composition. DXA is one of the most accurate and consistent techniques for evaluating body composition, particularly in quantifying fat mass, lean mass, and bone mineral density. The composition of the dominant lower limb thigh of the participant will be estimated using dual-energy X-ray absorptiometry with a Lunar Prodigy Advance device (GE Healthcare, Chicago, IL, USA). According to the manufacturer's recommendations, prior to scanning, participants will be asked to remove all removable metal-containing objects (e.g., jewelry, glasses, clothing with buttons or zippers). Scans will be performed with participants lying in a supine position along the longitudinal axis of the scanner table's centerline. The feet will be tied together to immobilize the legs, while the hands will be placed in a prone position within the scanning region. All assessments will be conducted by the same examiner. DXA

    Time frame: Baseline, 6 weeks, end of intervention (12 weeks) and follow-up (16weeks)

  3. Rigidity of the leg extensor muscles assessed by ultrasound elastography

    To analyze stiffness by elastography, an ultrasound device (Nemio XG, Toshiba, Japan), tape measure, dermographic pen, and water-soluble gel will be used. Muscle thickness (MT, mm) and subcutaneous fat thickness (SFT, mm) of the vastus lateralis, rectus femoris, and vastus intermedius muscles of the right limb will be measured using B-mode imaging using an ultrasound device (Nemio XG, Toshiba, Japan) with a 7.5 MHz linear probe (38 mm depth, 90 dB gain). Before imaging begins, to allow for the distribution of body fluids, participants will lie supine for 5 minutes with their lower limbs extended and relaxed, and must remain in this position throughout the assessment. A water-soluble gel, which promotes acoustic contact without applying pressure to the skin, will be applied to the assessment site, and the transducer will be positioned perpendicular to the assessed muscles.

    Time frame: Baseline, 6 weeks, end of intervention (12 weeks) and follow-up (16weeks)

  4. Muscle power of knee extensors using a linear potentiometer (Peak Power, CEFISE)

    The linear potentiometer (Peak Power, CEFISE) consists of an electronic system interfaced to software that measures the displacement speed of any body within a range of up to 2.5 meters. The speed is measured by a precision stopwatch connected to a wire that can be attached to the dumbbell or weight column of the equipment. The use of a linear encoder to assess power has been proven to be safe in people with Parkinson's disease. Muscle power will be assessed on the KONNEN GYM® knee machine.

    Time frame: Baseline, 6 weeks, end of intervention (12 weeks) and follow-up (16weeks)

  5. Functional capacity through the CounterMovement Jump - CMJ

    The analysis of the vertical jump allows the collection of several metrics (flight time, exit speed and joint angle). Based on these measurements, it is possible to estimate other significant values such as muscle power of the lower limbs and jump height. A verification of the complete movement can be performed (separation of each stage and the influence of these stages on the performance of the individuals) or, in a more simplified way, only the height of the jump can be considered. This estimate is generally made based on the flight time and assuming constant acceleration of the individual's center of mass. To obtain these metrics, we will use a force platform (Cefise - Jump, System Pro, software version 1.0, Brazil). The signal will be captured at a frequency of 1000 Hz and the force platform will be calibrated before all tests according to the manufacturer's instructions.

    Time frame: Baseline, 6 weeks, end of intervention (12 weeks) and follow-up (16weeks)

  6. Sit-to-Stand Five Times Test

    The TSLCV can be used to assess functional mobility, including risk of falling, balance and measurement of lower limb strength in people with Parkinson's. The individual begins the test sitting in a chair without arms and is instructed to stand with arms crossed over the chest; with full extension of the hips and knees, returning to a sitting position with the back supported by the vertical back of the chair. It should be repeated 5 times sequentially and without interruption; recording the total time taken to perform the test. A risk of falling is suggested when the individual performs the test for more than 16 seconds.

    Time frame: Baseline, 6 weeks, end of intervention (12 weeks) and follow-up (16weeks)

  7. Postural assessment using the NeuroPostureApp

    The postural assessment will be performed using the NeuroPostureApp application, which is available free of charge in full (http://www.neuroimaging.uni-kiel.de/NeuroPostureApp). This instrument allows you to use a photo in a lateral view to assess camptocormia using the reference points (lateral malleolus, L5 and C7).

    Time frame: Baseline, 6 weeks, end of intervention (12 weeks) and follow-up (16weeks)

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Dec 2026, 13 months after the start.

Of 1,297 non-industry interventional studies with no phase under Parkinson Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 13 months is below that.

Counting every sponsor, half of 1,373 studies reached it within 25 months; a quarter within 11 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 28, 2025
First posted
Sep 15, 2025
StartActual
Nov 1, 2025
Primary completionEst.
Dec 1, 2026
CompletionEst.
Dec 1, 2026
Last update
Aug 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07172698
Responsible party
Fernanda Cechetti (Professor, PhD, Federal University of Health Science of Porto Alegre) — Principal investigator
First posted
Sep 15, 2025
Start date
Nov 1, 2025
Primary completion
Dec 1, 2026 (estimated)
Completion
Dec 1, 2026 (estimated)
Last update
Aug 31, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion